Soliman Says… 5 Questions Every RNA Platform Must Answer Before Investors Write The Check

By William A. Soliman, Ph.D., BCMAS, Founder and Chief Investment Officer, White Manna Capital Partners & Founder/CEO, Accreditation Council for Medical Affairs (ACMA)

RNA can rewrite the rules of drug development. It cannot repeal the rules of disciplined investing.

The word “platform” has become one of biotechnology’s most valuable and most abused terms. In an investor presentation, it implies repeatability, speed, multiple shots on goal and economics that improve with every new program. But too often, what is described as a platform is a single promising asset surrounded by a collection of preclinical possibilities.  It reminds me of when a company claims to be an “AI” company. Are they really?

Undoubtedly, RNA therapeutics deserve serious attention and let’s be honest, the field has moved well beyond a scientific thought experiment to becoming a major driver of important pharmacological options for patients. The FDA’s approval of patisiran established RNA interference as a therapeutic modality, while subsequent products have shown that chemically modified oligonucleotides and targeted delivery can produce clinically meaningful medicines. Messenger RNA vaccines demonstrated another important feature: once the underlying system works, the informational payload can be changed faster than a conventional biologic can be rebuilt.

However, scientific validation of RNA as a modality is not the same as validation of every company calling itself an RNA platform. Investors must distinguish between modality risk, platform risk, asset risk and financing risk. A company may be operating in a validated modality while still possessing weak delivery technology, undifferentiated intellectual property, fragile manufacturing or a pipeline it cannot afford to develop.

Before investors write the check, management should be able to answer these five questions:

1. Is this truly a platform or one asset with a platform narrative?

A real platform produces transferable learning. The first program should reduce the time, cost or probability of failure for the second. The second should strengthen the case for the third. If every candidate requires a new delivery vehicle, a new manufacturing process, a new toxicology strategy and a new regulatory argument, the company may have a portfolio, but it does not yet have a platform.

Investors should ask management to identify what remains constant across programs. Is it the RNA chemistry? The targeting ligand? The lipid nanoparticle composition? The manufacturing process? The computational design engine? The analytical package? Then ask what data demonstrate that these components behave predictably when the sequence, target or disease changes.

The strongest evidence is not the number of pipeline circles on a slide. It is repeatable performance across distinct molecules: comparable potency, exposure, tissue distribution, tolerability and manufacturability. A platform earns a premium only when knowledge compounds. Otherwise, investors should value the lead asset on its own merits and assign little or no value to the rest of the pipeline.

2. Can the company deliver the RNA to the right cells at a therapeutic dose?

For RNA therapeutics, delivery is often the business. Designing a sequence may be increasingly fast; delivering it to the intended tissue, achieving cellular uptake, escaping the endosome and sustaining a useful biological effect remain much harder.

Success in the liver cannot automatically be extrapolated to the lung, muscle, central nervous system, solid tumors or immune-cell subsets. The liver has been an attractive proving ground partly because biology and delivery technologies such as GalNAc conjugation make hepatocyte targeting comparatively tractable. Companies moving beyond the liver must show that biodistribution is not merely detectable but therapeutically meaningful and that the dose required does not create an unacceptable safety or cost burden.

Investors should look for quantitative answers: What percentage of the administered dose reaches the target tissue? Which cell types actually receive functional cargo? How much escapes intracellular degradation? What is the duration of expression or knockdown? Does repeat dosing change efficacy, immunogenicity or tolerability? Recent research continues to identify endosomal escape as a major bottleneck for mRNA delivery. That matters because impressive in vitro potency can disappear when confronted with the physics and biology of an intact human body.

A platform that cannot reliably reach the desired cell is not a drug-development platform. It is a sequence-design capability waiting for a delivery solution.

3. Does the platform create regulatory leverage or only more regulatory complexity?

One of the most attractive claims in platform biotechnology is that regulators will permit prior knowledge to carry forward. That is possible, but it should never be assumed. The FDA’s Platform Technology Designation Program is important because it recognizes that a well-understood technology incorporated into multiple products may support efficiencies in development and review. The critical words, however, are well understood.

Investors should ask what elements of the nonclinical, chemistry, manufacturing and controls, and safety packages can reasonably be reused. Has the company held regulator meetings that support this position? Are the products manufactured using the same process and controls? Does changing the payload alter biodistribution, innate immune activation, off-target effects or product quality attributes? What comparability work will be required after scale-up or formulation changes?

The regulatory value of a platform grows only after the company accumulates credible, product-specific evidence. Early-stage companies often model future programs as though the first candidate will pay all the platform’s regulatory tuition. In practice, regulators review products, not PowerPoint architectures. A genuine platform may create leverage, but it must earn that leverage through consistency, characterization and clinical experience.

4. Can the company repeatedly manufacture at scale and at a commercially viable cost?

RNA programs can move quickly from design to candidate selection, which creates a dangerous illusion that the rest of development will move at the same speed. Manufacturing frequently becomes the hidden constraint.

Investors should examine yield, purity, encapsulation efficiency, particle-size consistency, residual impurities, stability, cold-chain requirements and release testing. They should also ask whether the process that produced early clinical material can support pivotal trials and commercial demand. A program that depends on heroic batch-by-batch adjustments is not scalable, even if every batch eventually passes.

The economic questions are equally important. What is the cost per dose at the current scale and at the proposed commercial scale? How sensitive is gross margin to RNA length, dose level, frequency of administration or lipid composition? Does the company control critical raw materials and intellectual property, or is it dependent on scarce suppliers and overlapping licenses? Can the same manufacturing infrastructure serve multiple programs without creating a scheduling bottleneck?

A platform should generate operating leverage. If each new candidate adds roughly the same technical burden and capital requirement as the first, the platform may expand scientific opportunity while simultaneously destroying financial discipline.

5. Can the financing strategy survive the time required to prove the platform?

This is the question scientists understandably dislike and investors cannot avoid. A technically elegant platform can still be a poor investment if the company must finance five years of development in two years of capital.

Management teams often defend broad pipelines as diversification. In reality, too many programs can dilute expertise, delay decisive data and force financing at the worst possible time. Investors should model the company’s cash runway to a value-inflecting clinical readout — not merely to the next regulatory filing. They should also test what happens if enrollment takes six months longer, manufacturing costs rise, a partnership is delayed or the lead asset produces ambiguous rather than clearly positive data.

The best RNA companies will sequence risk. They will select an initial indication where delivery is feasible, biomarkers are measurable, clinical proof of mechanism can be obtained efficiently and the commercial opportunity supports further investment. They will use partnerships strategically without surrendering the assets that best validate the platform. Most importantly, they will know which programs not to fund.

Cash discipline is not separate from platform strategy. It determines whether the company will remain solvent long enough to demonstrate that the platform exists.

The Investor’s Bottom Line

RNA is one of the most consequential therapeutic technologies of the modern biopharmaceutical era. It offers the ability to intervene upstream in biology, address targets that conventional small molecules and antibodies may not reach, and potentially reuse technical infrastructure across multiple medicines. Those advantages are real.

But the investment conclusion should not begin with “RNA works.” It should begin with a harder question: What does this specific company know how to do repeatedly that others cannot easily reproduce?

A truly investable RNA platform should demonstrate five forms of leverage: scientific leverage across candidates, delivery leverage across relevant cells or tissues, regulatory leverage through accumulated knowledge, manufacturing leverage through repeatable processes, and financial leverage through disciplined program selection. Weakness in any one can impair the entire enterprise.

The most dangerous platform companies are not necessarily those with bad science. They are those with good science, expansive narratives and insufficient evidence that success can be repeated economically. Investors should resist paying today for every indication that could theoretically appear on a pipeline slide tomorrow.

The right check is written when the data show that the platform is becoming more valuable with each program and the company has the capital discipline to let that compounding occur.

Selected Sources

• U.S. Food and Drug Administration. New Class of Drugs Fulfills Promise of RNA-based Medicine; FDA approval history for patisiran and RNA interference.
• U.S. Food and Drug Administration. Platform Technology Designation Program for Drug Development: guidance implementing section 506K of the FD&C Act.
• U.S. Food and Drug Administration. LEQVIO (inclisiran) prescribing information, including GalNAc-facilitated delivery to hepatocytes.
• Nature Reviews Chemistry. Xiong S, Liu C. Core mission: mRNA endosomal escape. 2025.
• Nature Reviews Drug Discovery. RNA chemistry and therapeutics. 2025.

About The Author

https://img-resizer.vertmarkets.com/resize?size=&variable=file2&sourceurl=https://vertassets.blob.core.windows.net/image/108f8946/108f8946-a349-4325-9d0a-5f5eed540239/dr_william_soliman.jpgWilliam Soliman, Ph.D., is the founder & CEO of the Accreditation Council for Medical Affairs (ACMA) and the founder & CEO of White Manna Capital Partners, a biotech/pharma focused hedge fund. The ACMA is the leading life sciences accreditation, certification, and training company in the world and established the first ever certification standards for prior authorization, reimbursement, pharma sales, medical science liaisons, and medical affairs professionals. Soliman is considered a pharmaceutical industry futurist. In March 2021, he testified before the United States Congress’ Energy and Commerce Health Subcommittee about the pharmaceutical industry and the importance of professional standards for those who directly engage healthcare providers, like sales representatives. Soliman is a former pharmaceutical executive who held leadership roles at several Big Pharma companies, including Merck, Johnson & Johnson, AbbVie, and Gilead. He is routinely featured on media outlets such as NewsNation, Fox News, ABC News, Forbes, Al Jazeera, Yahoo! Finance, Yahoo! Business TV, and more. Soliman received his Ph.D. from Columbia University and his bachelor’s degree from New York University.